Tifcemalimab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A recombinant humanized immunoglobulin G4 kappa (IgG4k) monoclonal antibody directed against B- and T-lymphocyte attenuator (BTLA), with potential immunomodulating and antineoplastic activities. Upon intravenous infusion administration, tifcemalimab targets and binds to BTLA. This prevents BTLA-mediated inhibition of T-cell activation leading to antigen specific T-cell proliferation and activation of a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. BTLA, an immunoglobulin (Ig) receptor family member expressed on activated T- and B- lymphocytes, subsets of dendritic cells (DCs), macrophages, and nature killer (NK) cells, is an immune checkpoint involved in suppressing immune responses. It mediates inhibition of human tumor-specific CTLs upon engagement by tumor expressed herpesvirus-entry mediator (HVEM).

**Synonyms:** - Anti-B- and T-lymphocyte Attenuator Monoclonal Antibody TAB004 - Anti-BTLA Monoclonal Antibody TAB004 - Icatolimab - JS 004 - JS-004 - JS004 - TAB 004 - TAB-004 - TAB004 - TIFCEMALIMAB